C-X-C ligand 10 and C-X-C receptor 3 status can predict tamoxifen treatment response in breast cancer patients

Breast Cancer Research and Treatment

Volumn 145, Issue 1, 2014, Pages 73-82

  Hilborn, Erik ^a   Sivik, Tove ^a   Fornander, Tommy ^b   Stål, Olle ^a,c   Nordenskjöld, Bo ^a,c   Jansson, Agneta ^a  

^a LINKÖPING UNIVERSITY   (Sweden)

^b KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^c Operations and Specialty Surgery Center   (Sweden)

Author keywords

CXCL10; CXCR3; Endocrine treatment; Prognosis; Tamoxifen

Indexed keywords

CHEMOKINE RECEPTOR CXCR3; ESTROGEN RECEPTOR; GAMMA INTERFERON INDUCIBLE PROTEIN 10; TAMOXIFEN; ANTINEOPLASTIC HORMONE AGONISTS AND ANTAGONISTS; CXCL10 PROTEIN, HUMAN; TUMOR MARKER;

ARTICLE; BREAST CANCER; CANCER PROGNOSIS; CANCER SPECIFIC SURVIVAL; CANCER STAGING; CONTROLLED STUDY; DRUG RESPONSE; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LOCAL RECURRENCE FREE SURVIVAL; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; PROTEIN EXPRESSION; RANDOMIZED CONTROLLED TRIAL (TOPIC); TISSUE MICROARRAY; TREATMENT OUTCOME; BREAST NEOPLASMS; COHORT ANALYSIS; KAPLAN MEIER METHOD; METABOLISM; MORTALITY; PROGNOSIS; PROPORTIONAL HAZARDS MODEL; RANDOMIZED CONTROLLED TRIAL; RETROSPECTIVE STUDY;

ANTINEOPLASTIC AGENTS, HORMONAL; BREAST NEOPLASMS; CHEMOKINE CXCL10; COHORT STUDIES; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; KAPLAN-MEIER ESTIMATE; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; RECEPTORS, CXCR3; RETROSPECTIVE STUDIES; TAMOXIFEN; TISSUE ARRAY ANALYSIS; TUMOR MARKERS, BIOLOGICAL;

EID: 84900470184     PISSN: 01676806     EISSN: 15737217     Source Type: Journal    
DOI: 10.1007/s10549-014-2933-7     Document Type: Article

References (35)

1. Groom JR, Luster AD (2011) CXCR3 ligands: redundant, collaborative and antagonistic functions. Immunol Cell Biol 89(2):207-215. doi: 10.1038/icb.2010.158
2. Kajitani K, Tanaka Y, Arihiro K, Kataoka T, Ohdan H (2012) Mechanistic analysis of the antitumor efficacy of human natural killer cells against breast cancer cells. Breast Cancer Res Treat 134(1):139-155. doi: 10.1007/s10549-011- 1944-x
3. Luster AD, Leder P (1993) IP-10, a -C-X-C- chemokine, elicits a potent thymus-dependent antitumor response in vivo. J Exp Med 178(3):1057-1065
4. Taub DD, Lloyd AR, Conlon K, Wang JM, Ortaldo JR, Harada A, Matsushima K, Kelvin DJ, Oppenheim JJ (1993) Recombinant human interferon-inducible protein 10 is a chemoattractant for human monocytes and T lymphocytes and promotes T cell adhesion to endothelial cells. J Exp Med 177(6):1809-1814
5. Cole KE, Strick CA, Paradis TJ, Ogborne KT, Loetscher M, Gladue RP, Lin W, Boyd JG, Moser B, Wood DE, Sahagan BG, Neote K (1998) Interferon-inducible T cell alpha chemoattractant (I-TAC): a novel non-ELR CXC chemokine with potent activity on activated T cells through selective high affinity binding to CXCR3. J Exp Med 187(12):2009-2021
6. Arenberg DA, Kunkel SL, Polverini PJ, Morris SB, Burdick MD, Glass MC, Taub DT, Iannettoni MD, Whyte RI, Strieter RM (1996) Interferon-gamma-inducible protein 10 (IP-10) is an angiostatic factor that inhibits human non-small cell lung cancer (NSCLC) tumorigenesis and spontaneous metastases. J Exp Med 184(3):981-992
7. Giuliani N, Bonomini S, Romagnani P, Lazzaretti M, Morandi F, Colla S, Tagliaferri S, Lasagni L, Annunziato F, Crugnola M, Rizzoli V (2006) CXCR3 and its binding chemokines in myeloma cells: expression of isoforms and potential relationships with myeloma cell proliferation and survival. Haematologica 91(11):1489-1497
8. Goldberg-Bittman L, Neumark E, Sagi-Assif O, Azenshtein E, Meshel T, Witz IP, Ben-Baruch A (2004) The expression of the chemokine receptor CXCR3 and its ligand, CXCL10, in human breast adenocarcinoma cell lines. Immunol Lett 92(1-2):171-178
9. Lo BK, Yu M, Zloty D, Cowan B, Shapiro J, McElwee KJ (2010) CXCR3/ligands are significantly involved in the tumorigenesis of basal cell carcinomas. Am J Pathol 176(5):2435-2446
10. Zipin-Roitman A, Meshel T, Sagi-Assif O, Shalmon B, Avivi C, Pfeffer RM, Witz IP, Ben-Baruch A (2007) CXCL10 promotes invasion-related properties in human colorectal carcinoma cells. Cancer Res 67(7):3396-3405
11. Persano L, Moserle L, Esposito G, Bronte V, Barbieri V, Iafrate M, Gardiman MP, Larghero P, Pfeffer U, Naschberger E, Sturzl M, Indraccolo S, Amadori A (2009) Interferon-alpha counteracts the angiogenic switch and reduces tumor cell proliferation in a spontaneous model of prostatic cancer. Carcinogenesis 30(5):851-860
12. Dorsey R, Kundu N, Yang Q, Tannenbaum CS, Sun H, Hamilton TA, Fulton AM (2002) Immunotherapy with interleukin-10 depends on the CXC chemokines inducible protein-10 and monokine induced by IFN-gamma. Cancer Res 62(9):2606-2610
13. Hu J, You S, Li W, Wang D, Nagpal ML, Mi Y, Liang P, Lin T (1998) Expression and regulation of interferon-gamma-inducible protein 10 gene in rat Leydig cells. Endocrinology 139(8):3637-3645
14. Chu Y, Yang X, Xu W, Wang Y, Guo Q, Xiong S (2007) In situ expression of IFN-gamma-inducible T cell alpha chemoattractant in breast cancer mounts an enhanced specific anti-tumor immunity which leads to tumor regression. Cancer Immunol Immunother 56(10):1539-1549. doi: 10.1007/s00262-007-0296-1
15. Datta D, Flaxenburg JA, Laxmanan S, Geehan C, Grimm M, Waaga-Gasser AM, Briscoe DM, Pal S (2006) Ras-induced modulation of CXCL10 and its receptor splice variant CXCR3-B in MDA-MB-435 and MCF-7 cells: relevance for the development of human breast cancer. Cancer Res 66(19):9509-9518
16. Ma X, Norsworthy K, Kundu N, Rodgers WH, Gimotty PA, Goloubeva O, Lipsky M, Li Y, Holt D, Fulton A (2009) CXCR3 expression is associated with poor survival in breast cancer and promotes metastasis in a murine model. Mol Cancer Ther 8(3):490-498
17. Lasagni L, Francalanci M, Annunziato F, Lazzeri E, Giannini S, Cosmi L, Sagrinati C, Mazzinghi B, Orlando C, Maggi E, Marra F, Romagnani S, Serio M, Romagnani P (2003) An alternatively spliced variant of CXCR3 mediates the inhibition of endothelial cell growth induced by IP-10, Mig, and I-TAC, and acts as functional receptor for platelet factor 4. J Exp Med 197(11):1537-1549
18. Wu Q, Dhir R, Wells A (2012) Altered CXCR3 isoform expression regulates prostate cancer cell migration and invasion. Mol Cancer 11(1):3. doi: 10.1186/1476-4598-11-3
19. Aronica SM, Fanti P, Kaminskaya K, Gibbs K, Raiber L, Nazareth M, Bucelli R, Mineo M, Grzybek K, Kumin M, Poppenberg K, Schwach C, Janis K (2004) Estrogen disrupts chemokine-mediated chemokine release from mammary cells: implications for the interplay between estrogen and IP-10 in the regulation of mammary tumor formation. Breast Cancer Res Treat 84(3):235-245. doi: 10.1023/B:BREA.0000019961.59306.f6
20. Curigliano G (2011) Immunity and autoimmunity: revising the concepts of response to breast cancer. Breast 20(Suppl 3):S71-S74. doi: 10.1016/S0960- 9776(11)70298-3
21. Schild-Hay LJ, Leil TA, Divi RL, Olivero OA, Weston A, Poirier MC (2009) Tamoxifen induces expression of immune response-related genes in cultured normal human mammary epithelial cells. Cancer Res 69(3):1150-1155. doi: 10.1158/0008-5472.CAN-08-2806
22. McShane LM, Altman DG, Sauerbrei W, Taube SE, Gion M, Clark GM, Statistics Subcommittee of NCIEWGoCD (2006) Reporting recommendations for tumor marker prognostic studies (REMARK). Breast Cancer Res Treat 100(2):229-235. doi: 10.1007/s10549-006-9242-8
23. Rutqvist LE, Johansson H, Stockholm Breast Cancer Study Group (2007) Long-term follow-up of the randomized Stockholm trial on adjuvant tamoxifen among postmenopausal patients with early stage breast cancer. Acta Oncol 46(2):133-145
24. Jansson A, Delander L, Gunnarsson C, Fornander T, Skoog L, Nordenskjold B, Stal O (2009) Ratio of 17HSD1 to 17HSD2 protein expression predicts the outcome of tamoxifen treatment in postmenopausal breast cancer patients. Clin Cancer Res 15(10):3610-3616
25. Aronica SM, Raiber L, Hanzly M, Kisela C (2009) Antitumor/antiestrogenic effect of the chemokine interferon inducible protein 10 (IP-10) involves suppression of VEGF expression in mammary tissue. J Interferon Cytokine Res 29(2):83-92. doi: 10.1089/jir.2008.0034
26. Aksoy MO, Yang Y, Ji R, Reddy PJ, Shahabuddin S, Litvin J, Rogers TJ, Kelsen SG (2006) CXCR3 surface expression in human airway epithelial cells: cell cycle dependence and effect on cell proliferation. Am J Physiol Lung Cell Mol Physiol 290(5):L909-L918
27. Romagnani P, Annunziato F, Lasagni L, Lazzeri E, Beltrame C, Francalanci M, Uguccioni M, Galli G, Cosmi L, Maurenzig L, Baggiolini M, Maggi E, Romagnani S, Serio M (2001) Cell cycle-dependent expression of CXC chemokine receptor 3 by endothelial cells mediates angiostatic activity. J Clin Investig 107(1):53-63
28. Janis K, Hoeltke J, Nazareth M, Fanti P, Poppenberg K, Aronica SM (2004) Estrogen decreases expression of chemokine receptors, and suppresses chemokine bioactivity in murine monocytes. Am J Reprod Immunol 51(1):22-31
29. Kawada K, Sonoshita M, Sakashita H, Takabayashi A, Yamaoka Y, Manabe T, Inaba K, Minato N, Oshima M, Taketo MM (2004) Pivotal role of CXCR3 in melanoma cell metastasis to lymph nodes. Cancer Res 64(11):4010-4017
30. Cambien B, Karimdjee BF, Richard-Fiardo P, Bziouech H, Barthel R, Millet MA, Martini V, Birnbaum D, Scoazec JY, Abello J, Al Saati T, Johnson MG, Sullivan TJ, Medina JC, Collins TL, Schmid-Alliana A, Schmid-Antomarchi H (2009) Organ-specific inhibition of metastatic colon carcinoma by CXCR3 antagonism. Br J Cancer 100(11):1755-1764. doi: 10.1038/sj.bjc.6605078
31. Kawada K, Hosogi H, Sonoshita M, Sakashita H, Manabe T, Shimahara Y, Sakai Y, Takabayashi A, Oshima M, Taketo MM (2007) Chemokine receptor CXCR3 promotes colon cancer metastasis to lymph nodes. Oncogene 26(32):4679-4688. doi: 10.1038/sj.onc.1210267
32. Mulligan AM, Raitman I, Feeley L, Pinnaduwage D, Nguyen LT, O'Malley FP, Ohashi PS, Andrulis IL (2013) Tumoral lymphocytic infiltration and expression of the chemokine CXCL10 in breast cancers from the Ontario Familial Breast Cancer Registry. Clin Cancer Res 19(2):336-346. doi: 10.1158/1078-0432.CCR-11-3314
33. Nejatollahi F, Ranjbar R, Younesi V, Asgharpour M (2013) Deregulation of HER2 downstream signaling in breast cancer cells by a cocktail of anti-HER2 scFvs. Oncol Res 20(8):333-340. doi: 10.3727/096504013X13657689382734
34. Gacci M, Serni S, Lapini A, Vittori G, Alessandrini M, Nesi G, Palli D, Carini M (2009) CXCR3-B expression correlates with tumor necrosis extension in renal cell carcinoma. J Urol 181(2):843-848. doi: 10.1016/j.juro.2008.10.063
35. Datta D, Banerjee P, Gasser M, Waaga-Gasser AM, Pal S (2010) CXCR3-B can mediate growth-inhibitory signals in human renal cancer cells by down-regulating the expression of heme oxygenase-1. J Biol Chem 285(47):36842-36848